Article
How and Why to Submit Your Project for SHM Converge 2023
June 1, 2022
Today’s the day to start thinking about submitting a scholarly project to SHM Converge 2023. Our job is to convince you why it’s important and show you how to proceed. Our advice is based on our...
Article
SHM 2022 Awards of Excellence and Junior Investigator Award
June 1, 2022
SHM’s Awards of Excellence Program honors members who’ve made exceptional contributions to hospital medicine in a variety of categories. Clinical Leadership for Physicians Marisha Burden, MD,...
Article
Things to do in Nashville
March 1, 2022
Sights, sounds, food, and fun! You might know Nashville as the birthplace of country music and home to SHM’s 2022 annual conference, Converge—but there’s a lot more to see and do in...
Article
Must-attend Converge sessions
March 1, 2022
SHM editorial board members share their picks Each year, hospitalists, clinicians, and frontline workers come together for SHM’s annual conference—Converge. They come for education, engagement,...
Article
SHM Converge promises a lively return to live
February 3, 2022
In 1998, about 200 hospitalists and hospital medicine-related professionals came together in San Diego at the first annual conference of the National Association of Inpatient Physicians (NAIP). The...
News
Epilepsy linked to 1.5-fold higher COVID-19 mortality in hospital
December 14, 2021
Findings suggest higher risk although researchers haven’t adjusted findings for confounders yet.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
